Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.48 |
| ▸ | EP300 | Q09472 | 3/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 3/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16651736 | 0.90 | BRD4 (0.46) | BRD4EP300PTGS2HSPB1 | |
| SCHEMBL21190853 | 0.87 | BRD4 (0.45) | BRD4EP300PTGS2METKDR | |
| SCHEMBL21190878 | 0.86 | BRD4 (0.48) | BRD4EP300PTGS2METKDR | |
| SCHEMBL20155140 | 0.84 | PTGS2 (0.51) | BRD4PTGS2HSPB1MAPK14 | |
| SCHEMBL31073743 | 0.83 | HSPB1 (0.38) | BRD4PTGS2HSPB1 | |
| SCHEMBL16651407 | 0.82 | BRD4 (0.47) | BRD4PTGS2HSPB1 | |
| SCHEMBL21190843 | 0.81 | BRD4 (0.45) | BRD4PTGS2METKDRGSK3A | |
| SCHEMBL16650216 | 0.81 | BRD4 (0.50) | BRD4EP300PTGS2 | |
| SCHEMBL29533045 | 0.81 | HSPB1 (0.39) | BRD4PTGS2HSPB1MAPK14 | |
| SCHEMBL15069672 | 0.81 | HSPB1 (0.39) | BRD4PTGS2HSPB1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4134364-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11884680-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4134364-A2 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-4134364-A2 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| EP-3640241-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2022-09-28 | — | — | EP | disclosed |
| CN-108558889-B | Bromodomain inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2021-11-05 | — | — | CN | disclosed |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-08-05 | — | — | US | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
| WO-2015058160-A1 | BROMODOMAIN INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015058160-A1 | BROMODOMAIN INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2015-04-23 | — | — | WO | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
| EP-2797918-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| WO-2014165143-A1 | DIHYDRO-PYRROLOPYRIDINONE BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140275026-A1 | DIHYDRO-PYRROLOPYRIDINONE INHIBITORS | ABBVIE INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-06-12 | — | — | US | disclosed |
| WO-2013097601-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885EP300 2/4885PTGS2 2757/4885 |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | BRD4 1/4885EP300 33/4885PTGS2 1807/4885 |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885EP300 2/4885PTGS2 2757/4885 |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885EP300 2/4885PTGS2 2757/4885 |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | BRD4 1/4885EP300 33/4885PTGS2 1807/4885 |
| US-20140275026-A1 | DIHYDRO-PYRROLOPYRIDINONE INHIBITORS | DPYD, QDPR, DHFR | BRD4 676/4885EP300 1147/4885PTGS2 840/4885 |
| US-11884680-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | BRD4 5/4885EP300 2/4885PTGS2 2757/4885 |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | BRD4 1/4885EP300 33/4885PTGS2 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.